Article
Exendin-4 alleviates hepatic steatosis by lowering FABP1 and raising FOXA1 expression via the Wnt/-catenin signaling pathway
2021-09-23
Abstract excerpt
Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Agonists of the glucagon-like peptide-1 receptor (GLP-1R), currently approved to treat type 2 diabetes, hold promise to improve steatosis and even steatohepatitis. However, due to their pleiotropic effects, the mechanisms underlying their protective effect on NAFLD remain elusive. We aimed to investigate these mechanisms usin...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 50e6f832-c492-519e-9235-82fff86d20b4
- DOI
- 10.21203/rs.3.rs-898584/v1
